BioMedWire Stocks

Research Finds That Tourism, Travel May Boost Mental Health

A new study has suggested that tourism should be viewed as an industry that offers real health benefits, in addition to being viewed as a recreational experience. The study, which was conducted by researchers at the Center for Precision Health at the Edith Cowan University in collaboration with the School of Business and Law, discovered that various aspects of being on holiday could have a positive influence on individuals with mental health conditions.

Dr. Jun Wen, the study’s lead researcher, stated that the diverse team of experts on public health, tourism and marketing looked into how tourism could benefit individuals with dementia. Wen explained that medical experts recommended dementia treatments such as reminiscence therapy, cognitive stimulation, exercise, music therapy, sensory stimulation and adaptations to a patient’s environment and mealtimes. He revealed that these treatments could often be found when on holiday, making this one of the first studies to conceptually talk about how tourism experiences could be used as dementia interventions.

Wen also discussed tourism’s varied nature, which meant that there were numerous opportunities to incorporate treatments for mental health conditions. For instance, undergoing new experiences and being in a new environment could offer sensory and cognitive stimulation. Travelling also involves more physical activity such as walking, which could be good for individuals with such conditions, as exercise has been associated with better mental well-being.

Wen also talked about how mealtimes on holidays were different because they were often social affairs involving multiple individuals, which could positively impact the eating behaviors of patients with dementia. Other basics often found on holidays, such as sunshine and fresh air, which increased serotonin and vitamin D levels, were also a plus for the patients.

In the report, Wen also talked about how the pandemic had affected travel in the recent years, raising questions about its value beyond economic and lifestyle factors. He stated that studies had shown that tourism boosted psychological and physical well-being, arguing that now was a good time to identify the place tourism held in public health, particularly for vulnerable groups.

In the study report, Wen added that he hoped new collaborative research could look into how tourism had improved the lives of individuals living with a myriad of conditions. He also revealed that the researchers were focused on doing something to bridge health science and tourism, noting that more empirical research and evidence was needed to see whether tourism could become a medical intervention for different ailments such as depression and dementia.

For individuals whose mental health issues may be too severe to improve when they engage in travel or tourism, the remedies being developed by companies such as Silo Pharma Inc. (OTCQB: SILO) from psychedelic substances may provide the needed turning point toward improved health.

NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment

Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams…

4 days ago

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether…

5 days ago

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology…

7 days ago

Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy

For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients…

7 days ago

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis)…

1 week ago

Survey Finds That US Healthcare Workers Worry About Personal Safety

According to a new survey, approximately 60% of workers in the U.S. healthcare sector are…

2 weeks ago